Advisor Group Holdings, Inc. Cerevel Therapeutics Holdings, Inc. Transaction History

Advisor Group Holdings, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$38.96 - $42.75 $3,701 - $4,061	95 Added 118.75%	175 $7,000
Q1 2024 May 10, 2024	BUY	$40.88 - $43.27 $817 - $865	20 Added 33.33%	80 $3,000
Q4 2023 Feb 12, 2024	SELL	$20.27 - $42.44 $1,216 - $2,546	-60 Reduced 50.0%	60 $2,000
Q3 2023 Nov 13, 2023	BUY	$20.26 - $31.91 $1,215 - $1,914	60 Added 100.0%	120 $2,000
Q1 2023 May 12, 2023	SELL	$22.82 - $35.32 $114 - $176	-5 Reduced 7.69%	60 $1,000
Q3 2022 Nov 14, 2022	SELL	$25.5 - $41.42 $6,477 - $10,520	-254 Reduced 79.62%	65 $2,000
Q2 2022 Aug 10, 2022	BUY	$20.62 - $37.15 $804 - $1,448	39 Added 13.93%	319 $9,000
Q1 2022 May 04, 2022	BUY	$23.5 - $35.38 $6,580 - $9,906	280 New	280 $10,000

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.